1422851-67-9

Basic information

• Product Name: N¹-((1R,2R)-2-(aminomethyl)-2,3-dihydro-1H-inden-1-yl)-N²-(4-chloro-3-fluorophenyl)-oxalamide
• Synonyms: N¹-((1R,2R)-2-(aminomethyl)-2,3-dihydro-1H-inden-1-yl)-N²-(4-chloro-3-fluorophenyl)-oxalamide
• CAS NO: 1422851-67-9
• Molecular Weight: 361.803
• Mol File: 1422851-67-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N¹-((1R,2R)-2-(aminomethyl)-2,3-dihydro-1H-inden-1-yl)-N²-(4-chloro-3-fluorophenyl)-oxalamide(CAS DataBase Reference)
• NIST Chemistry Reference: N¹-((1R,2R)-2-(aminomethyl)-2,3-dihydro-1H-inden-1-yl)-N²-(4-chloro-3-fluorophenyl)-oxalamide(1422851-67-9)
• EPA Substance Registry System: N¹-((1R,2R)-2-(aminomethyl)-2,3-dihydro-1H-inden-1-yl)-N²-(4-chloro-3-fluorophenyl)-oxalamide(1422851-67-9)

Safety Data

• Hazardous Substances Data: 1422851-67-9(Hazardous Substances Data)

Upstream product

• 7480-35-5 (1S,2R)-1-amino-2-indanol 
• 480451-89-6 methyl 2-(4-chloro-3-fluoroanilino)-2-oxoacetate 
• 367-22-6 4-chloro-3-fluoroaniline 
• 904295-56-3 (1S,2R)-1-[(tert-butoxycarbonyl)amino]-2,3-dihydro-1H-inden-2-yl methanesulfonate 
• 1422851-66-8 N¹-(4-chloro-3-fluorophenyl)-N²-((1R,2R)-2-(hydroxymethyl)-2,3-dihydro-1H-inden-1-yl)oxalamide 
• 55269-97-1 [(1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl] methanol 
• 135053-20-2 (1R,2R)-1-amino-2,3-dihydro-1H-indene-2-carboxylic acid 
• 1226789-23-6 ethyl 2-((4-chloro-3-fluorophenyl)amino)-2-oxoacetate 
• 95-13-6 1-indene 
• 1422851-70-4 [(1R,2S)-1-{(2-((4-chloro-3-fluorophenyl)amino)-2-oxoacetamido)-2,3-dihydro-1H-inden-2-yl}methyl] methanesulfonate 
• 1422851-50-0 N¹-(4-chloro-3-fluorophenyl)-N²-((1R,2S)-2-(hydroxymethyl)-2,3-dihydro-1H-inden-1-yl)oxalamide 

Downstream Products

• 1422851-31-7 (+)-N¹-(4-chloro-3-fluorophenyl)-N²-(trans-2-(guanidinomethyl)indan-1-yl)oxalamide formate salt 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral gp120 receptor (e.g., temsavir, BMS-818251, DMJ-ll-121, BNM-IV-147, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin- binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., HIV infections).

Structure-based design and synthesis of an HIV-1 entry inhibitor exploiting X-ray and thermodynamic characterization

The design, synthesis, thermodynamic and crystallographic characterization of a potent, broad spectrum, second-generation HIV-1 entry inhibitor that engages conserved carbonyl hydrogen bonds within gp120 has been achieved. The optimized antagonist exhibits a submicromolar binding affinity (110 nM) and inhibits viral entry of clade B and C viruses (IC50 geometric mean titer of 1.7 and 14.0 μM, respectively), without promoting CD4-independent viral entry. The thermodynamic signatures indicate a binding preference for the (R,R)- over the (S,S)-enantiomer. The crystal structure of the small-molecule/gp120 complex reveals the displacement of crystallographic water and the formation of a hydrogen bond with a backbone carbonyl of the bridging sheet. Thus, structure-based design and synthesis targeting the highly conserved and structurally characterized CD4-gp120 interface is an effective tactic to enhance the neutralization potency of small-molecule HIV-1 entry inhibitors.